1,681,360 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Equity Investment Corp

Key Points

• Equity Investment Corp acquired 1.68 million Zimmer Biomet shares worth approximately $144.7 million, making ZBH its 11th-largest holding and representing 0.87% of the company. Institutional investors collectively own 88.89% of Zimmer Biomet.
• Zimmer Biomet exceeded quarterly expectations, reporting $2.07 in adjusted EPS and $2.18 billion in revenue, with revenue up 4.8% year over year. The company maintained fiscal 2026 EPS guidance of $8.47–$8.59.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $104.42; shares recently opened at $99.31. Zimmer Biomet also pays a quarterly dividend of $0.24, equal to a 1.0% annualized yield.

Equity Investment Corp acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,681,360 shares of the medical equipment provider's stock, valued at approximately $144,748,000. Zimmer Biomet comprises 2.8% of Equity Investment Corp's portfolio, making the stock its 11th largest holding. Equity Investment Corp owned 0.87% of Zimmer Biomet at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. DV Equities LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at $25,000. Monetary Solutions Ltd acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $30,000. Gen Wealth Partners Inc acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $31,000. Elevation Wealth Partners LLC boosted its position in shares of Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider's stock valued at $33,000 after acquiring an additional 229 shares during the period. Finally, Cornerstone Financial Management LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the company's stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company's stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.28% of the company's stock.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of recent research reports. Weiss Ratings upgraded Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Tuesday, August 4th. Citigroup lowered their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a "neutral" rating for the company in a research note on Thursday, May 28th. Royal Bank Of Canada upped their price target on Zimmer Biomet from $101.00 to $110.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. Barclays dropped their price objective on shares of Zimmer Biomet from $100.00 to $94.00 and set an "underweight" rating on the stock in a research note on Wednesday, April 29th. Finally, Zacks Research lowered Zimmer Biomet from a "hold" rating to a "strong sell" rating in a report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and an average target price of $104.42.

Zimmer Biomet Trading Up 1.1%

Shares of ZBH stock opened at $99.31 on Wednesday. The firm has a market cap of $18.94 billion, a P/E ratio of 24.16, a price-to-earnings-growth ratio of 3.20 and a beta of 0.45. The business has a 50-day moving average price of $91.91 and a two-hundred day moving average price of $90.74. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $108.29.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the firm posted $2.07 earnings per share. The business's revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.53 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend was Thursday, June 25th. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source